Navigation Links
mobileMICROMEDE™

ProductsmobileMICROMEDE™
Company Thomson Micromedex
Item mobileMICROMEDE™
Features 
  • PDA topics include: Drug Information, Drug Interaction Tool, Diagnosis Tool, Acute Care Information, Toxicology Information, Alternative Medicine Information, Whats New
  • Automatically updated every month
  • Consistent with the information found in Micromedex™ Healthcare Series
  • Runs efficiently from memory expansion cards
Description mobileMICROMEDEX™ gives physicians, pharmacists, and other healthcare professionals reliable clinical information to help support and confirm treatment decisions. Clinicians can trust the data in mobileMICROMEDEX because all information undergoes a thorough, unbiased editorial process.
Info Thomson Micromedex
Customer Service: +1(303) 486-6400
Web site: http://www.micromedex.com/index.html

Related medicine products :

1. Concise Guide to Drug Interaction Principles for Medical Practice
2. Drug Facts - Gold (A to Z Drugs and Drug Interaction)
3. Drug Interaction Facts: Herbal Supplements & Food
4. The Medical Letters Handbook of Adverse Drug Interactions
5. Drug Facts - Platinum (A to Z, Natural Products and Drug Interaction)
6. Just the Facts in Emergency Medicine
7. A to Z Drug Facts
8. A to Z Drug Facts, 6th Edition
9. Drug Facts - Silver (A to Z Drug Facts with Auto-Updates)
10. Fast Facts: Orthopaedic Review
Breaking Medicine Technology:Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 2Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 3Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 1Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 2Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 53675 3Clarient Reports Second Quarter Revenue Up 40 Percent 53673 1Clarient Reports Second Quarter Revenue Up 40 Percent 53673 2Clarient Reports Second Quarter Revenue Up 40 Percent 53673 3Clarient Reports Second Quarter Revenue Up 40 Percent 53673 4Clarient Reports Second Quarter Revenue Up 40 Percent 53673 5Clarient Reports Second Quarter Revenue Up 40 Percent 53673 6Clarient Reports Second Quarter Revenue Up 40 Percent 53673 7Clarient Reports Second Quarter Revenue Up 40 Percent 53673 8Clarient Reports Second Quarter Revenue Up 40 Percent 53673 9Clarient Reports Second Quarter Revenue Up 40 Percent 53673 10Cambrex Reports Second Quarter 2009 Results 53671 1Cambrex Reports Second Quarter 2009 Results 53671 2Cambrex Reports Second Quarter 2009 Results 53671 3Cambrex Reports Second Quarter 2009 Results 53671 4Cambrex Reports Second Quarter 2009 Results 53671 5Cambrex Reports Second Quarter 2009 Results 53671 6Cambrex Reports Second Quarter 2009 Results 53671 7Cambrex Reports Second Quarter 2009 Results 53671 8Cambrex Reports Second Quarter 2009 Results 53671 9Cambrex Reports Second Quarter 2009 Results 53671 10Cambrex Reports Second Quarter 2009 Results 53671 11Cambrex Reports Second Quarter 2009 Results 53671 12